Biotalys Nv · EURONEXT:BTLS

Biotalys Nv — H1 2025 Earnings Presentation

14 slides from Biotalys Nv's earnings presentation, Sep 18, 2025

  1. Slide 1: First-Half 2025 Results

    First-Half 2025 Results 18 September 2025

  2. Slide 2: Disclaimer

    Disclaimer • This presentation, including the oral presentation (together, the “Materials”) has been prepared by the management of Biotalys NV (the “Company”). The Materials must be treated confidentially and may not be distributed, passed on or otherwise disclosed. The Materials serve information p

  3. Slide 3: Kevin Helash, CEO

    ¥ biotalys Kevin Helash, CEO

  4. Slide 4: Key investment highlights

    Key investment highlights 1 Growing market in need of innovation World is outgrowing traditional crop protection and demanding safe, sustainable and novel solutions. Biologically-based solutions are the fastest growing category in a $40bn market of fungicides & insecticides 1 2 Leadership position i

  5. Slide 5: Biotalys continues to advance toward commercialization

    Biotalys continues to advance toward commercialization EVOCATM is paving the way for Biotalys' pipeline... ... While securing a breakthrough market position Regulatory ✓ Limited competition on similar approaches • EPA expected to finalize registration in Q4 2025 ✓ No competitor as advanced in R&D, r

  6. Slide 6: Leadership position in new Precision Biocontrols category

    Leadership position in new Precision Biocontrols category Biotalys is pioneering Precision Biocontrols, a new category in the $40bn fungicide & insecticide market: reliability and scale of chemical solutions with safety and environmental profile of biologicals Traditional biologicals Precision Bioco

  7. Slide 7: Clear partnering strategy empowering pipeline development

    Clear partnering strategy empowering pipeline development Deal structure customized to partner capabilities, resources and interests 1 2 3 4 5 Traditional Upfront payments Cost compensation Milestone payments Royalties distribution Partnering guarantees scalable, economically-sustainable pipeline gr

  8. Slide 8: BioFun-6 second-generation fungicide demonstrating excellent performance with lower dose rates

    BioFun-6 second-generation fungicide demonstrating excellent performance with lower dose rates Field trial results Field trial description • Trials commissioned by Biotalys and conducted by CRO’s in Europe and the U.S. • The BioFun-6 AGROBODY candidate: ✓ performs as well as a chemical and as EVOCA

  9. Slide 9: Luc Van fraeyenhoven, CFO

    ¥ biotalys Luc Van fraeyenhoven, CFO

  10. Slide 10: HY 2025 key financial highlights

    HY 2025 key financial highlights In € thousands June 30, 2025 June 30, 2024 Other operating income 1,379 1,452 Research and development expenses (6,520) (5,135) General and administrative expenses (2,988) (2,890) Operating loss (8,129) (6,574) Loss of the period (8,135) (6,489) Net cash used in oper

  11. Slide 11: Biotalys is committed to disciplined capital deployment

    Biotalys is committed to disciplined capital deployment Past years Present Future Cash burn reduced by c. 40% since 20221 Consider funding options to finance the next Innovation and financial discipline value inflection points 25.000 Cash burn in EURk 20.000 Complete key regulatory approvals Capital

  12. Slide 12: Key investment highlights

    Key investment highlights 1 Growing market in need of innovation World is outgrowing traditional crop protection and demanding safe, sustainable and novel solutions. Biologically-based solutions are the fastest growing category in a $40bn market of fungicides & insecticides 1 2 Leadership position i

  13. Slide 13: Q&A

    Q&A Kevin Helash Luc Van fraeyenhoven Chief Executive Officer Chief Financial Officer 13

  14. Slide 14: Slide 14

Biotalys — H1 2025 Earnings Presentation on 6ix